Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Spine J ; 16(2): e77-82, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26523960

ABSTRACT

BACKGROUND CONTEXT: Our case highlights the underappreciated thrombotic risks of tranexamic acid (TXA) use in non-cardiac surgery and emphasizes the need to elucidate these risks with appropriate clinical trials. PURPOSE: The use of TXA in non-cardiac surgery has significantly expanded in the past 5 years, especially after the 2010 publication of the CRASH-2 Trial. We submit a case with the intent to highlight the thrombotic risk of TXA use during non-cardiac surgery and discuss the need for careful risk stratification before the use of TXA in this context. STUDY DESIGN: A 66-year-old man with long-standing HIV infection, hypertension, and no history of coronary artery disease (CAD) presented for revision spinal fusion surgery with the use of TXA is presented. METHODS: To limit perioperative blood loss, the case patient received TXA intraoperatively. His operative course was uneventful. RESULTS: During the first 12 hours postoperatively the patient was noted to have persistent tachycardia and ST-elevation on electrocardiogram. Echocardiography showed a new apical wall motion abnormality and a left ventricle thrombus; cardiac catheterization confirmed two-vessel CAD, treated with a bare-metal stent and anticoagulation. CONCLUSIONS: The thrombotic risks of TXA use in non-cardiac surgery have yet to be adequately studied in clinical trials. Hence, TXA use in this context is still an area of uncertainty, and its thrombogenic risks have yet to be studied as a primary outcome in any large prospective trial to date. Patients with any hypercoagulable risk factors, including HIV infection or any prior thrombotic history in which TXA use is being considered, should prompt a discussion among the perioperative physicians involved.


Subject(s)
Antifibrinolytic Agents/adverse effects , Heart Diseases/chemically induced , Spine/surgery , Thrombosis/chemically induced , Tranexamic Acid/adverse effects , Aged , Antifibrinolytic Agents/therapeutic use , HIV Infections/complications , Heart Ventricles/pathology , Humans , Male , Neurosurgical Procedures/adverse effects , Tranexamic Acid/therapeutic use
3.
Anesth Analg ; 120(3): 570-575, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25695574

ABSTRACT

Aspirin constitutes important uninterrupted lifelong therapy for many patients with cardiovascular (CV) disease or significant (CV) risk factors. However, whether aspirin should be continued or withheld in patients undergoing noncardiac surgery is a common clinical conundrum that balances the potential of aspirin for decreasing thrombotic risk with its possibility for increasing perioperative blood loss. In this focused review, we describe the role of aspirin in treating and preventing cardiovascular disease, summarize the most important literature on the perioperative use of aspirin (including the recently published PeriOperative ISchemic Evaluation [POISE]-2 trial), and offer current recommendations for managing aspirin during the perioperative period. POISE-2 suggests that aspirin administration during the perioperative period does not change the risk of a cardiovascular event and may result in increased bleeding. However, these findings are tempered by a number of methodological issues related to the study. On the basis of currently available literature, including POISE-2, aspirin should not be administered to patients undergoing surgery unless there is a definitive guideline-based primary or secondary prevention indication. Aside from closed-space procedures, intramedullary spine surgery, or possibly prostate surgery, moderate-risk patients taking lifelong aspirin for a guideline-based primary or secondary indication may warrant continuation of their aspirin throughout the perioperative period.


Subject(s)
Aspirin/administration & dosage , Cardiovascular Diseases/drug therapy , Cardiovascular Diseases/prevention & control , Fibrinolytic Agents/administration & dosage , Platelet Aggregation Inhibitors/administration & dosage , Randomized Controlled Trials as Topic , Surgical Procedures, Operative , Aspirin/adverse effects , Cardiovascular Diseases/blood , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/mortality , Drug Administration Schedule , Fibrinolytic Agents/adverse effects , Humans , Perioperative Care , Platelet Aggregation Inhibitors/adverse effects , Postoperative Hemorrhage/chemically induced , Primary Prevention , Randomized Controlled Trials as Topic/methods , Research Design , Risk Assessment , Risk Factors , Secondary Prevention , Surgical Procedures, Operative/adverse effects , Surgical Procedures, Operative/mortality , Time Factors , Treatment Outcome
9.
J Clin Anesth ; 25(3): 193-7, 2013 May.
Article in English | MEDLINE | ID: mdl-23523573

ABSTRACT

STUDY OBJECTIVE: To determine which of two facemask grip techniques for two-person facemask ventilation was more effective in novice clinicians, the traditional E-C clamp (EC) grip or a thenar eminence (TE) technique. DESIGN: Prospective, randomized, crossover comparison study. SETTING: Operating room of a university hospital. SUBJECTS: 60 novice clinicians (medical and paramedic students). MEASUREMENTS: Subjects were assigned to perform, in a random order, each of the two mask-grip techniques on consenting ASA physical status 1, 2, and 3 patients undergoing elective general anesthesia while the ventilator delivered a fixed 500 mL tidal volume (VT). In a crossover manner, subjects performed each facemask ventilation technique (EC and TE) for one minute (12 breaths/min). The primary outcome was the mean expired VT compared between techniques. As a secondary outcome, we examined mean peak inspiratory pressure (PIP). MAIN RESULTS: The TE grip provided greater expired VT (379 mL vs 269 mL), with a mean difference of 110 mL (P < 0.0001; 95% CI: 65, 157). Using the EC grip first had an average VT improvement of 200 mL after crossover to the TE grip (95% CI: 134, 267). When the TE grip was used first, mean VTs were greater than for EC by 24 mL (95% CI: -25, 74). When considering only the first 12 breaths delivered (prior to crossover), the TE grip resulted in mean VTs of 339 mL vs 221 mL for the EC grip (P = 0.0128; 95% CI: 26, 209). There was no significant difference in PIP values using the two grips: the TE mean (SD) was 14.2 (7.0) cm H2O, and the EC mean (SD) was 13.5 (9.0) cm H2O (P = 0.49). CONCLUSIONS: The TE facemask ventilation grip results in improved ventilation over the EC grip in the hands of novice providers.


Subject(s)
Clinical Competence , Masks , Respiration, Artificial/standards , Adult , Allied Health Personnel/education , Anesthesiology/education , Cross-Over Studies , Education, Medical/methods , Female , Humans , Life Support Care/methods , Life Support Care/standards , Male , Middle Aged , New Mexico , Respiration, Artificial/instrumentation , Respiration, Artificial/methods
10.
Ann Surg ; 255(5): 811-9, 2012 May.
Article in English | MEDLINE | ID: mdl-22470078

ABSTRACT

OBJECTIVE: To provide an evidence-based focused review of aspirin use in the perioperative period along with an in-depth discussion of the considerations and risks associated with its preoperative withdrawal. BACKGROUND: For patients with established cardiovascular disease, taking aspirin is considered a critical therapy. The cessation of aspirin can cause a platelet rebound phenomenon and prothrombotic state leading to major adverse cardiovascular events. Despite the risks of aspirin withdrawal, which are exacerbated during the perioperative period, standard practice has been to stop aspirin before elective surgery for fear of excessive bleeding. Mounting evidence suggests that this practice should be abandoned. METHODS: We performed a PubMed and Medline literature search using the keywords aspirin, withdrawal, and perioperative. We manually reviewed relevant citations for inclusion. RESULTS/CONCLUSIONS: Clinicians should employ a patient-specific strategy for perioperative aspirin management that weighs the risks of stopping aspirin with those associated with its continuation. Most patients, especially those taking aspirin for secondary cardiovascular prevention, should have their aspirin continued throughout the perioperative period. When aspirin is held preoperatively, the aspirin withdrawal syndrome may significantly increase the risk of a major thromboembolic complication. For many operative procedures, the risk of perioperative bleeding while continuing aspirin is minimal, as compared with the concomitant thromboembolic risks associated with aspirin withdrawal. Those cases where aspirin should be stopped include patients undergoing intracranial, middle ear, posterior eye, intramedullary spine, and possibly transurethral prostatectomy surgery.


Subject(s)
Aspirin/therapeutic use , Hemorrhage/etiology , Perioperative Care , Platelet Aggregation Inhibitors/therapeutic use , Aspirin/pharmacology , Blood Platelets/drug effects , Cardiac Surgical Procedures , Cardiovascular Diseases/prevention & control , Humans , Mohs Surgery , Orthopedic Procedures , Perioperative Period , Platelet Aggregation Inhibitors/pharmacology , Thrombosis/prevention & control , Urologic Surgical Procedures , Vascular Surgical Procedures
SELECTION OF CITATIONS
SEARCH DETAIL
...